Hemab Therapeutics (COAG) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026Sutacimig in Glanzmann thrombasthenia
Phase III single-arm design selected after constructive regulatory dialogue to control variability; trial targets 90% power to detect a minimum 50% effect.
Annualized treated bleed rate is the primary endpoint; regulators endorsed endpoints, dose and analysis plan, supported by a validated electronic bleed diary.
~75 patients to enroll across multiple countries and sites; U.S. and two non-U.S. regions are open, with enrollment and timing metrics planned for H1 2027.
Phase II low-dose weekly results showed a 50% reduction in the intention-to-treat analysis and ~80% per-protocol; the pivotal design is powered for a minimum 50% effect.
Trial aims for broad eligibility among an estimated 800-1,000 U.S. patients; HEMLIBRA is a pricing reference, with ~$800,000 list cost and ~$650,000 average after weight adjustments.
Factor VII deficiency and broader potential
First clinical data showed up to a five-fold increase in total Factor VII and >50% reduction in prothrombin time; mutation-informed analysis may help predict responders.
Initial U.K. site results support adding countries and sites; more data are needed to finalize dose and regimen, with potential to leverage Glanzmann safety data.
The estimated 5,000 Factor VII patients reflect the severe population; moderate patients could expand reach if treatment is safe and effective.
Potential future sutacimig indications include Bernard-Soulier syndrome, other platelet disorders and treatment-resistant hemophilia A and B.
HMB-002 for von Willebrand disease
Data from 13 patients across 20, 50 and 150 mg cohorts showed dose proportionality and ~2.5-fold increases in von Willebrand factor and Factor VIII, normalizing average levels in the studied population.
February EAHAD update planned with a 300 mg single-ascending-dose cohort and initial 150 mg monthly multiple-dose data; 8-10 additional patients are expected to bring total data to over 20 patients.
Phase II is assessing prospectively collected annualized treated bleeds; at least 50% reduction is a preliminary efficacy benchmark, with minimum four-month baseline and up to four months of treatment follow-up.
2027 is the expected timeframe to understand requirements for transition; management expects phase I/II could lead directly to a single pivotal trial.
Monovalent antibody targets residual endogenous von Willebrand factor; initial focus is type 1 and 2A, representing an estimated 90%-95% of patients, with data planned for February.
Latest events from Hemab Therapeutics
- SOLARA launches as the pipeline advances, backed by runway into 2029.COAG
Q3 2026 - Innovative therapies show strong early results for rare coagulation disorders, advancing to late-stage trials.COAG
Corporate presentation - Net loss rose to $46.8M as R&D spending increased; $457.5M cash funds operations into 2029.COAG
Q2 2026 - Advancing late-stage therapies for rare bleeding disorders with strong clinical and financial momentum.COAG
Jefferies Global Healthcare Conference 2026 - IPO raised $346.7M, extending cash runway into 2029 as R&D drives ongoing losses.COAG
Q1 2026 - IPO targets $231.4M to advance late-stage coagulation disorder therapies amid high risk.COAG
Registration filing - COO appointment, indemnification, and equity grants highlight management and offering structure.COAG
Registration filing - Biotech firm targeting rare bleeding disorders launches IPO to fund clinical trials and pipeline.COAG
Registration filing - Biotech IPO targets rare coagulation disorders, seeking funds for late-stage clinical trials.COAG
Registration filing